Review



rat tfa  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    MedChemExpress rat tfa
    (A) Protein levels of RAMP1 in Control and H/R groups with and <t>without</t> <t>CGRP</t> agonist. (B) Relative cell activity was determined by CCK-8 assay of RAMP1 in the control and H/R groups using a CGRP agonist. (C) CCK-8 assay was performed using CGRP agonists, YAP inhibitors, and agonists in H/R. (D) CCK-8 assay was performed using a CGRP agonist combined with an ERK inhibitor or agonist in H/R. (E) CCK-8 experiments were performed using ERK inhibitors in combination with YAP inhibitors or agonists in H/R. (F) CCK-8 assays were performed using ERK agonists combined with a YAP inhibitor or agonist in H/R. (G) Statistical analysis of flow cytometry to detect the proportion of apoptosis in H/R with a CGRP agonist, YAP inhibitor and agonist, and ERK inhibitor and agonist. (H) Statistical data in H/R, ERK inhibitor combined with YAP inhibitor or agonist were used to detect the proportion of apoptosis by flow cytometry. (I) Statistical data in H/R using ERK agonists combined with YAP inhibitors or agonists to detect the proportion of apoptosis. CGRP agonist: Caltonin gene-related peptide (CGRP) II, rat <t>TFA,</t> ERK agonist (C16-PAF); ERK inhibitor (SCH772984); YAP agonist (PY-60); and YAP inhibitor (Verteporfin). The cells were treated with apoptosis pathway inhibitors and subjected to 6 h of reperfusion after hypoxia. All data are presented as the mean ± SD. * p <0.05, ** p <0.01, *** p <0.001 using Student’s two-tailed t-test. CCK-8, cell counting Kit-8; CGRP agonist, caltonin gene-related peptide agonist; HIRI, hepatic ischemia-reperfusion injury.
    Rat Tfa, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rat+tfa/Calcitonin+Gene+Related+Peptide+(CGRP)+II%2C+rat/pmc11022058-67-94-98
    Average 92 stars, based on 1 article reviews
    rat tfa - by Bioz Stars, 2026-09
    92/100 stars

    Images

    1) Product Images from "RAMP1 Protects Hepatocytes against Ischemia-reperfusion Injury by Inhibiting the ERK/YAP Pathway"

    Article Title: RAMP1 Protects Hepatocytes against Ischemia-reperfusion Injury by Inhibiting the ERK/YAP Pathway

    Journal: Journal of Clinical and Translational Hepatology

    doi: 10.14218/JCTH.2023.00339

    (A) Protein levels of RAMP1 in Control and H/R groups with and without CGRP agonist. (B) Relative cell activity was determined by CCK-8 assay of RAMP1 in the control and H/R groups using a CGRP agonist. (C) CCK-8 assay was performed using CGRP agonists, YAP inhibitors, and agonists in H/R. (D) CCK-8 assay was performed using a CGRP agonist combined with an ERK inhibitor or agonist in H/R. (E) CCK-8 experiments were performed using ERK inhibitors in combination with YAP inhibitors or agonists in H/R. (F) CCK-8 assays were performed using ERK agonists combined with a YAP inhibitor or agonist in H/R. (G) Statistical analysis of flow cytometry to detect the proportion of apoptosis in H/R with a CGRP agonist, YAP inhibitor and agonist, and ERK inhibitor and agonist. (H) Statistical data in H/R, ERK inhibitor combined with YAP inhibitor or agonist were used to detect the proportion of apoptosis by flow cytometry. (I) Statistical data in H/R using ERK agonists combined with YAP inhibitors or agonists to detect the proportion of apoptosis. CGRP agonist: Caltonin gene-related peptide (CGRP) II, rat TFA, ERK agonist (C16-PAF); ERK inhibitor (SCH772984); YAP agonist (PY-60); and YAP inhibitor (Verteporfin). The cells were treated with apoptosis pathway inhibitors and subjected to 6 h of reperfusion after hypoxia. All data are presented as the mean ± SD. * p <0.05, ** p <0.01, *** p <0.001 using Student’s two-tailed t-test. CCK-8, cell counting Kit-8; CGRP agonist, caltonin gene-related peptide agonist; HIRI, hepatic ischemia-reperfusion injury.
    Figure Legend Snippet: (A) Protein levels of RAMP1 in Control and H/R groups with and without CGRP agonist. (B) Relative cell activity was determined by CCK-8 assay of RAMP1 in the control and H/R groups using a CGRP agonist. (C) CCK-8 assay was performed using CGRP agonists, YAP inhibitors, and agonists in H/R. (D) CCK-8 assay was performed using a CGRP agonist combined with an ERK inhibitor or agonist in H/R. (E) CCK-8 experiments were performed using ERK inhibitors in combination with YAP inhibitors or agonists in H/R. (F) CCK-8 assays were performed using ERK agonists combined with a YAP inhibitor or agonist in H/R. (G) Statistical analysis of flow cytometry to detect the proportion of apoptosis in H/R with a CGRP agonist, YAP inhibitor and agonist, and ERK inhibitor and agonist. (H) Statistical data in H/R, ERK inhibitor combined with YAP inhibitor or agonist were used to detect the proportion of apoptosis by flow cytometry. (I) Statistical data in H/R using ERK agonists combined with YAP inhibitors or agonists to detect the proportion of apoptosis. CGRP agonist: Caltonin gene-related peptide (CGRP) II, rat TFA, ERK agonist (C16-PAF); ERK inhibitor (SCH772984); YAP agonist (PY-60); and YAP inhibitor (Verteporfin). The cells were treated with apoptosis pathway inhibitors and subjected to 6 h of reperfusion after hypoxia. All data are presented as the mean ± SD. * p <0.05, ** p <0.01, *** p <0.001 using Student’s two-tailed t-test. CCK-8, cell counting Kit-8; CGRP agonist, caltonin gene-related peptide agonist; HIRI, hepatic ischemia-reperfusion injury.

    Techniques Used: Control, Activity Assay, CCK-8 Assay, Flow Cytometry, Two Tailed Test, Cell Counting

    Related Articles

    Phospho-proteomics:

    Article Title: RAMP1 Protects Hepatocytes against Ischemia-reperfusion Injury by Inhibiting the ERK/YAP Pathway
    Article Snippet: During the detection, the culture medium was replaced, 10 μL CCK-8 (KGA317-2, KeyGEN) and 100μL culture medium (C11875500BT, GIBCO) were added to each well, and incubated at 37°C for 2 h. Finally, the absorbance at 450 nm was measured using a microplate reader. .. YAP phosphorylation inhibitor: Truli (E1061, Selleck, 0.2 nm) and PY-60 (HY-141644, MCE; 1.6 μm; 10 mg/kg for mice in vivo , i.p. ); ERK phosphorylation inhibitor: Temuterkib (HY-101494, MCE; 5 nm) and SCH772984 (HY-50846, MCE; 300 nm, 5 mg/kg for mice in vivo , i.p. ); ERK agonist: C16-PAF(HY-108635, MCE, 1 μm , ); STAT3 inhibitor : Sttatic (HY-13818, MCE; IC50:10 μm); p-AKT inhibitor: MK2206 (HY-10358, MCE; 65 nm); Caspase-3 inhibitor: Z-VAD (HY-16658B, MCE; 10 μm ; 10 mg/kg for mice in vivo , i.p. ); CGRP agonist: Calcitonin Gene Related Peptide (CGRP) II, rat TFA (HY-P1913A , MCE; 83 μm ); Verteporfin (HY-B0146, MCE; 5 μm ). .. Caspase-3 activity assays were conducted using the Caspase-3 Activity Assay Kit (C1115, Beyotime), following previously established protocols., Briefly, liver tissue treated with pyrrolidine lysate was lysed using lysis buffer.

    In Vivo:

    Article Title: RAMP1 Protects Hepatocytes against Ischemia-reperfusion Injury by Inhibiting the ERK/YAP Pathway
    Article Snippet: During the detection, the culture medium was replaced, 10 μL CCK-8 (KGA317-2, KeyGEN) and 100μL culture medium (C11875500BT, GIBCO) were added to each well, and incubated at 37°C for 2 h. Finally, the absorbance at 450 nm was measured using a microplate reader. .. YAP phosphorylation inhibitor: Truli (E1061, Selleck, 0.2 nm) and PY-60 (HY-141644, MCE; 1.6 μm; 10 mg/kg for mice in vivo , i.p. ); ERK phosphorylation inhibitor: Temuterkib (HY-101494, MCE; 5 nm) and SCH772984 (HY-50846, MCE; 300 nm, 5 mg/kg for mice in vivo , i.p. ); ERK agonist: C16-PAF(HY-108635, MCE, 1 μm , ); STAT3 inhibitor : Sttatic (HY-13818, MCE; IC50:10 μm); p-AKT inhibitor: MK2206 (HY-10358, MCE; 65 nm); Caspase-3 inhibitor: Z-VAD (HY-16658B, MCE; 10 μm ; 10 mg/kg for mice in vivo , i.p. ); CGRP agonist: Calcitonin Gene Related Peptide (CGRP) II, rat TFA (HY-P1913A , MCE; 83 μm ); Verteporfin (HY-B0146, MCE; 5 μm ). .. Caspase-3 activity assays were conducted using the Caspase-3 Activity Assay Kit (C1115, Beyotime), following previously established protocols., Briefly, liver tissue treated with pyrrolidine lysate was lysed using lysis buffer.



    Similar Products

    rat mouse tfa targetmol chemicals inc  (TargetMol)
    93
    TargetMol rat mouse tfa targetmol chemicals inc
    Rat Mouse Tfa Targetmol Chemicals Inc, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rat+tfa/%CE%B2-Amyloid+(1-42)%2C+rat-mouse+TFA/bio_rxiv__2025__10__17__683079-315-37-39
    Average 93 stars, based on 1 article reviews
    rat mouse tfa targetmol chemicals inc - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    rat tfa  (MedChemExpress)
    92
    MedChemExpress rat tfa
    (A) Protein levels of RAMP1 in Control and H/R groups with and <t>without</t> <t>CGRP</t> agonist. (B) Relative cell activity was determined by CCK-8 assay of RAMP1 in the control and H/R groups using a CGRP agonist. (C) CCK-8 assay was performed using CGRP agonists, YAP inhibitors, and agonists in H/R. (D) CCK-8 assay was performed using a CGRP agonist combined with an ERK inhibitor or agonist in H/R. (E) CCK-8 experiments were performed using ERK inhibitors in combination with YAP inhibitors or agonists in H/R. (F) CCK-8 assays were performed using ERK agonists combined with a YAP inhibitor or agonist in H/R. (G) Statistical analysis of flow cytometry to detect the proportion of apoptosis in H/R with a CGRP agonist, YAP inhibitor and agonist, and ERK inhibitor and agonist. (H) Statistical data in H/R, ERK inhibitor combined with YAP inhibitor or agonist were used to detect the proportion of apoptosis by flow cytometry. (I) Statistical data in H/R using ERK agonists combined with YAP inhibitors or agonists to detect the proportion of apoptosis. CGRP agonist: Caltonin gene-related peptide (CGRP) II, rat <t>TFA,</t> ERK agonist (C16-PAF); ERK inhibitor (SCH772984); YAP agonist (PY-60); and YAP inhibitor (Verteporfin). The cells were treated with apoptosis pathway inhibitors and subjected to 6 h of reperfusion after hypoxia. All data are presented as the mean ± SD. * p <0.05, ** p <0.01, *** p <0.001 using Student’s two-tailed t-test. CCK-8, cell counting Kit-8; CGRP agonist, caltonin gene-related peptide agonist; HIRI, hepatic ischemia-reperfusion injury.
    Rat Tfa, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rat+tfa/Calcitonin+Gene+Related+Peptide+(CGRP)+II%2C+rat/pmc11022058-67-94-98
    Average 92 stars, based on 1 article reviews
    rat tfa - by Bioz Stars, 2026-09
    92/100 stars
    		  Buy from Supplier
    cgrp (83-119), rat tfa  (TargetMol)
    90
    TargetMol cgrp (83-119), rat tfa
    (A) Protein levels of RAMP1 in Control and H/R groups with and <t>without</t> <t>CGRP</t> agonist. (B) Relative cell activity was determined by CCK-8 assay of RAMP1 in the control and H/R groups using a CGRP agonist. (C) CCK-8 assay was performed using CGRP agonists, YAP inhibitors, and agonists in H/R. (D) CCK-8 assay was performed using a CGRP agonist combined with an ERK inhibitor or agonist in H/R. (E) CCK-8 experiments were performed using ERK inhibitors in combination with YAP inhibitors or agonists in H/R. (F) CCK-8 assays were performed using ERK agonists combined with a YAP inhibitor or agonist in H/R. (G) Statistical analysis of flow cytometry to detect the proportion of apoptosis in H/R with a CGRP agonist, YAP inhibitor and agonist, and ERK inhibitor and agonist. (H) Statistical data in H/R, ERK inhibitor combined with YAP inhibitor or agonist were used to detect the proportion of apoptosis by flow cytometry. (I) Statistical data in H/R using ERK agonists combined with YAP inhibitors or agonists to detect the proportion of apoptosis. CGRP agonist: Caltonin gene-related peptide (CGRP) II, rat <t>TFA,</t> ERK agonist (C16-PAF); ERK inhibitor (SCH772984); YAP agonist (PY-60); and YAP inhibitor (Verteporfin). The cells were treated with apoptosis pathway inhibitors and subjected to 6 h of reperfusion after hypoxia. All data are presented as the mean ± SD. * p <0.05, ** p <0.01, *** p <0.001 using Student’s two-tailed t-test. CCK-8, cell counting Kit-8; CGRP agonist, caltonin gene-related peptide agonist; HIRI, hepatic ischemia-reperfusion injury.
    Cgrp (83 119), Rat Tfa, supplied by TargetMol, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rat+tfa/CGRP+(83-119)%2C+rat+TFA/targetmol___tp1200
    Average 90 stars, based on 1 article reviews
    cgrp (83-119), rat tfa - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    nude mice  (TargetMol)
    90
    TargetMol nude mice
    (A) Protein levels of RAMP1 in Control and H/R groups with and <t>without</t> <t>CGRP</t> agonist. (B) Relative cell activity was determined by CCK-8 assay of RAMP1 in the control and H/R groups using a CGRP agonist. (C) CCK-8 assay was performed using CGRP agonists, YAP inhibitors, and agonists in H/R. (D) CCK-8 assay was performed using a CGRP agonist combined with an ERK inhibitor or agonist in H/R. (E) CCK-8 experiments were performed using ERK inhibitors in combination with YAP inhibitors or agonists in H/R. (F) CCK-8 assays were performed using ERK agonists combined with a YAP inhibitor or agonist in H/R. (G) Statistical analysis of flow cytometry to detect the proportion of apoptosis in H/R with a CGRP agonist, YAP inhibitor and agonist, and ERK inhibitor and agonist. (H) Statistical data in H/R, ERK inhibitor combined with YAP inhibitor or agonist were used to detect the proportion of apoptosis by flow cytometry. (I) Statistical data in H/R using ERK agonists combined with YAP inhibitors or agonists to detect the proportion of apoptosis. CGRP agonist: Caltonin gene-related peptide (CGRP) II, rat <t>TFA,</t> ERK agonist (C16-PAF); ERK inhibitor (SCH772984); YAP agonist (PY-60); and YAP inhibitor (Verteporfin). The cells were treated with apoptosis pathway inhibitors and subjected to 6 h of reperfusion after hypoxia. All data are presented as the mean ± SD. * p <0.05, ** p <0.01, *** p <0.001 using Student’s two-tailed t-test. CCK-8, cell counting Kit-8; CGRP agonist, caltonin gene-related peptide agonist; HIRI, hepatic ischemia-reperfusion injury.
    Nude Mice, supplied by TargetMol, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rat+tfa/Galanin+(1-16)%2C+mouse%2C+porcine%2C+rat+TFA/pmc07339020-93-23-52
    Average 90 stars, based on 1 article reviews
    nude mice - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    tfa ($54/mol, rat ld50 oral values 200−400 mg/kg)  (Thermo Fisher)
    90
    Thermo Fisher tfa ($54/mol, rat ld50 oral values 200−400 mg/kg)
    (A) Protein levels of RAMP1 in Control and H/R groups with and <t>without</t> <t>CGRP</t> agonist. (B) Relative cell activity was determined by CCK-8 assay of RAMP1 in the control and H/R groups using a CGRP agonist. (C) CCK-8 assay was performed using CGRP agonists, YAP inhibitors, and agonists in H/R. (D) CCK-8 assay was performed using a CGRP agonist combined with an ERK inhibitor or agonist in H/R. (E) CCK-8 experiments were performed using ERK inhibitors in combination with YAP inhibitors or agonists in H/R. (F) CCK-8 assays were performed using ERK agonists combined with a YAP inhibitor or agonist in H/R. (G) Statistical analysis of flow cytometry to detect the proportion of apoptosis in H/R with a CGRP agonist, YAP inhibitor and agonist, and ERK inhibitor and agonist. (H) Statistical data in H/R, ERK inhibitor combined with YAP inhibitor or agonist were used to detect the proportion of apoptosis by flow cytometry. (I) Statistical data in H/R using ERK agonists combined with YAP inhibitors or agonists to detect the proportion of apoptosis. CGRP agonist: Caltonin gene-related peptide (CGRP) II, rat <t>TFA,</t> ERK agonist (C16-PAF); ERK inhibitor (SCH772984); YAP agonist (PY-60); and YAP inhibitor (Verteporfin). The cells were treated with apoptosis pathway inhibitors and subjected to 6 h of reperfusion after hypoxia. All data are presented as the mean ± SD. * p <0.05, ** p <0.01, *** p <0.001 using Student’s two-tailed t-test. CCK-8, cell counting Kit-8; CGRP agonist, caltonin gene-related peptide agonist; HIRI, hepatic ischemia-reperfusion injury.
    Tfa ($54/Mol, Rat Ld50 Oral Values 200−400 Mg/Kg), supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rat+tfa/10__1021_slash_ol5006399-184-57-28
    Average 90 stars, based on 1 article reviews
    tfa ($54/mol, rat ld50 oral values 200−400 mg/kg) - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Protein levels of RAMP1 in Control and H/R groups with and without CGRP agonist. (B) Relative cell activity was determined by CCK-8 assay of RAMP1 in the control and H/R groups using a CGRP agonist. (C) CCK-8 assay was performed using CGRP agonists, YAP inhibitors, and agonists in H/R. (D) CCK-8 assay was performed using a CGRP agonist combined with an ERK inhibitor or agonist in H/R. (E) CCK-8 experiments were performed using ERK inhibitors in combination with YAP inhibitors or agonists in H/R. (F) CCK-8 assays were performed using ERK agonists combined with a YAP inhibitor or agonist in H/R. (G) Statistical analysis of flow cytometry to detect the proportion of apoptosis in H/R with a CGRP agonist, YAP inhibitor and agonist, and ERK inhibitor and agonist. (H) Statistical data in H/R, ERK inhibitor combined with YAP inhibitor or agonist were used to detect the proportion of apoptosis by flow cytometry. (I) Statistical data in H/R using ERK agonists combined with YAP inhibitors or agonists to detect the proportion of apoptosis. CGRP agonist: Caltonin gene-related peptide (CGRP) II, rat TFA, ERK agonist (C16-PAF); ERK inhibitor (SCH772984); YAP agonist (PY-60); and YAP inhibitor (Verteporfin). The cells were treated with apoptosis pathway inhibitors and subjected to 6 h of reperfusion after hypoxia. All data are presented as the mean ± SD. * p <0.05, ** p <0.01, *** p <0.001 using Student’s two-tailed t-test. CCK-8, cell counting Kit-8; CGRP agonist, caltonin gene-related peptide agonist; HIRI, hepatic ischemia-reperfusion injury.

    Journal: Journal of Clinical and Translational Hepatology

    Article Title: RAMP1 Protects Hepatocytes against Ischemia-reperfusion Injury by Inhibiting the ERK/YAP Pathway

    doi: 10.14218/JCTH.2023.00339

    Figure Lengend Snippet: (A) Protein levels of RAMP1 in Control and H/R groups with and without CGRP agonist. (B) Relative cell activity was determined by CCK-8 assay of RAMP1 in the control and H/R groups using a CGRP agonist. (C) CCK-8 assay was performed using CGRP agonists, YAP inhibitors, and agonists in H/R. (D) CCK-8 assay was performed using a CGRP agonist combined with an ERK inhibitor or agonist in H/R. (E) CCK-8 experiments were performed using ERK inhibitors in combination with YAP inhibitors or agonists in H/R. (F) CCK-8 assays were performed using ERK agonists combined with a YAP inhibitor or agonist in H/R. (G) Statistical analysis of flow cytometry to detect the proportion of apoptosis in H/R with a CGRP agonist, YAP inhibitor and agonist, and ERK inhibitor and agonist. (H) Statistical data in H/R, ERK inhibitor combined with YAP inhibitor or agonist were used to detect the proportion of apoptosis by flow cytometry. (I) Statistical data in H/R using ERK agonists combined with YAP inhibitors or agonists to detect the proportion of apoptosis. CGRP agonist: Caltonin gene-related peptide (CGRP) II, rat TFA, ERK agonist (C16-PAF); ERK inhibitor (SCH772984); YAP agonist (PY-60); and YAP inhibitor (Verteporfin). The cells were treated with apoptosis pathway inhibitors and subjected to 6 h of reperfusion after hypoxia. All data are presented as the mean ± SD. * p <0.05, ** p <0.01, *** p <0.001 using Student’s two-tailed t-test. CCK-8, cell counting Kit-8; CGRP agonist, caltonin gene-related peptide agonist; HIRI, hepatic ischemia-reperfusion injury.

    Article Snippet: YAP phosphorylation inhibitor: Truli (E1061, Selleck, 0.2 nm) and PY-60 (HY-141644, MCE; 1.6 µm; 10 mg/kg for mice in vivo , i.p. ); ERK phosphorylation inhibitor: Temuterkib (HY-101494, MCE; 5 nm) and SCH772984 (HY-50846, MCE; 300 nm, 5 mg/kg for mice in vivo , i.p. ); ERK agonist: C16-PAF(HY-108635, MCE, 1 µm , ); STAT3 inhibitor : Sttatic (HY-13818, MCE; IC50:10 µm); p-AKT inhibitor: MK2206 (HY-10358, MCE; 65 nm); Caspase-3 inhibitor: Z-VAD (HY-16658B, MCE; 10 µm ; 10 mg/kg for mice in vivo , i.p. ); CGRP agonist: Calcitonin Gene Related Peptide (CGRP) II, rat TFA (HY-P1913A , MCE; 83 µm ); Verteporfin (HY-B0146, MCE; 5 µm ).

    Techniques: Control, Activity Assay, CCK-8 Assay, Flow Cytometry, Two Tailed Test, Cell Counting